Search

Your search keyword '"Durukan M."' showing total 2 results
Start Over Author "Durukan M." Topic anticoagulants
2 results on '"Durukan M."'

1. An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design.

Author

Ertaş F, Kaya H, Yıldız A, Davutoğlu V, Kiriş A, Dinç L, Kafes H, Avcı A, Calapkorur B, Ertaş G, Gül M, Kahraman Ay N, Bulur S, Durukan M, Eren M, İlhan İ, Küçük M, Özpelit E, Şimşek H, Uçar FM, Yıldız A, Şahin DY, Ayhan E, Çağlayan CE, Güngör H, Özyurtlu F, Şen N, Vatan B, Vatansever F, Kobat MA, Temiz A, Taylan G, Dönmez İ, Erkuş ME, Söylemez S, Zengin H, Gündüz M, Tuncez A, Karavelioğlu Y, Gökdeniz T, Koza Y, Aktop Z, Katlandur H, Karaca Özer P, Yüksel M, Acet H, Çil H, Alan S, and Toprak N

Subjects
Humans, Turkey epidemiology, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Vitamin K antagonists & inhibitors
Abstract

Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients., Study Design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization)., Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016., Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).

Published
2015
Full Text
View/download PDF

2. Türkiye de nonvalvüler atriyum fibrilasyonlu hastalarda vitamin K antagonisti ve yeni oral antikoagülan kullanımı uygulamalarını değerlendirmek için epidemiyolojik çalışma - AFTER*-2 çalışması dizaynı

Author

Ertaş F., Kaya H., Yildiz A., Davuto?lu V., Kiriş A., Dinç L., Kafes H., Avci A., Calapkorur B., Ertaş G., Gül M., Ay N.K., Bulur S., Durukan M., Eren M., Ilhan I., Küçük M., Özpelit E., Şimşek H., Uçar F.M., Şahin D.Y., Ayhan E., Ça?layan C.E., Güngör H., Özyurtlu F., Şen N., Vatan B., Vatansever F., Kobat M.A., Temiz A., Taylan G., Dönmez I., Erkuş M.E., Söylemez S., Zengin H., Gündüz M., Tuncez A., Karavelio?lu Y., Gökdeniz T., Koza Y., Aktop Z., Katlandur H., Özer P.K., Yüksel M., Acet H., Çil H., Alan S., Toprak N., Hitit University, Ondokuz Mayıs Üniversitesi, Hitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çukurova Üniversitesi, Zonguldak Bülent Ecevit Üniversitesi, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı, Ertaş, Faruk, Kaya, Hasan, Yıldız, Abdulkadir, Çil, Habib, Yüksel, Murat, Acet, Halit, Alan, Sait, Toprak, Nizamettin, Kırıkkale Üniversitesi, and Hatay Mustafa Kemal Üniversitesi

Subjects
Uluslararası düzeltme oranı, lcsh:Diseases of the circulatory (Cardiovascular) system, Vitamin K, Turkey, lcsh:Medicine, Disease, anticoagulant agent, Electrocardiography, Atrial Fibrillation, Epidemiology, Atrial fibrillation/epidemiology, Stroke, medicine.diagnostic_test, Atrial fibrillation, Vitamin K antagonist, Cardiology, İlaç kullanımı, Varfarin, Cardiology and Cardiovascular Medicine, drug utilization, Anticoagulant agent, medicine.medical_specialty, lcsh:Internal medicine, medicine.drug_class, electrocardiography, Kalp ve Kalp Damar Sistemi, Drug utilization, International normalized ratio, Warfarin, Mitral valve stenosis, Antikoagülan ilaç, Internal medicine, medicine, Humans, cardiovascular diseases, Adverse effect, lcsh:RC31-1245, Elektrokardiyografi, business.industry, atrial fibrillation/epidemiology, international normalized ratio, lcsh:R, Anticoagulants, warfarin, medicine.disease, Atriyum fibrilasyonu/epidemiyoloji, lcsh:RC666-701, business
Abstract

WOS: 000421963600007, PubMed: 25782122, Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials. gov number, NCT02354456.).

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results